Ipilimumab is a CTLA-4 inhibitor approved for melanoma, renal cell carcinoma, microsatellite instability–high, or mismatch repair deficiency colorectal cancer [1]. Here, CTLA4 is linked to hereditary clear cell renal cell carcinoma.